Targeting B cells in Graves' disease

Endocrinology. 2006 Oct;147(10):4559-60. doi: 10.1210/en.2006-0852.
No abstract available

Publication types

  • Comment

MeSH terms

  • Animals
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents / pharmacology
  • Autoimmunity / physiology
  • B-Cell Activation Factor Receptor
  • B-Lymphocytes / immunology*
  • Graves Disease / immunology*
  • Humans
  • Membrane Proteins / metabolism
  • Membrane Proteins / physiology
  • Receptors, Tumor Necrosis Factor / metabolism
  • Rituximab
  • Tumor Necrosis Factor Ligand Superfamily Member 13
  • Tumor Necrosis Factor-alpha / physiology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • B-Cell Activation Factor Receptor
  • Membrane Proteins
  • Receptors, Tumor Necrosis Factor
  • TNFRSF13C protein, human
  • TNFSF13 protein, human
  • Tumor Necrosis Factor Ligand Superfamily Member 13
  • Tumor Necrosis Factor-alpha
  • Rituximab